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The prevalence, course and prognosis of mitral valve pro- 
lapse are just beginning to be defined, and the concepts of 
benign variant and multifacwial etiolwies are iust bezinnine 
to be recognized. In this respect, D&n et al. (I) den& 
strated unusual foresight in 1963 by initialing a prospective, 
personal follow-up of symptomatic patients with idiopathic 
mitral valve prolapse. However, their findings of serious 
complications in IO0 of 300 patients, reported in this issue of 
the Journal (I), are in contradistinction to recent reports that 
I) de-emphasize the prevalence of serious r,mplications, 
and 2) questton the specificity of many findings previously 
thought 10 be typical of mitral valve prolapse. 
General research design. The methodology used by Du. 
ren et al. (1) relies on the relative metirs of detailed, long- 
term clinical follow-up by committed observers. However, 
the data must be interpreted cautiously as they do not 
include a contml group, which would be needed for rigorous 
epidemiologic analysis. As pointed out by the authors, the 
cohort is a spccitic subset of patients with mitral valve 
prokwe: I) they were symptomatic; 2) many had evidence 
of mitral reauraitation on presentation: and 3) thev war- 
ranted naninvasive or inva&e diagnostic stud&. Th; latter 
bias may be most marked in early patients whose symptom 
complex justified cardiac catheterization and who were 
followed up for the longest interval. Close follow-up itself 
enxurages relative “over-reporting,” and the terms “corn- 
plications” and “symptomatic” imply a cause and effect 
relation; a comparison group is required to sumxwt the 
validity of such conch&u. &lly, t.he term “serious cam- 
plication” is stibjectwe, and the condition of even pa:ients 
with ventricular tachycardia remained remarkably stable. 
Speclc ltmitations imposed by the absence of ca,wrret,t 
controls. Duren et al. (I) report on 21(9R of 300 wdients 
with supraventticular and Xl (1%) of 300 pat&s with 
ventricular arrhythmias. Although an excess of arrhythmias 
in patients with mitral valve prolapse may be detected (2). 
the Framingham study (3) ofbasically asymptomatic patients 
with mitral valve prolapse defined by M-mode echocardiog- 
raphy detected supraventricular arrhythmias in 25% and 
pairs or runs of ventricular premature depolarizations in 20% 
of their cohort. Arrhythmia was so frequent in concurrent 
control patients that a significant difference in arrhythmia 
frequency could not bedetected. Recently, Kligiieldetal. (4) 
suggested that arrhythmia is a function of mitral regurgita- 
tion rather than the specific etiology, namely, mitral valve 
prolapse. 
Duren et al. (I) also retard three sudden deaths and IS 
total deaths, I3 of which were cardiac, in 1,830 patient- 
years. This figure is intermediate between the estimated risk 
of sudden death in nonselected patients with mitral valve 
prolapse of 1.9 per lO,Ci~3 patients per year and the all-cause 
sudden death raw of 22 per lO,ooO patients in the U. S. adult 
papulatian (X6!. The total mortality is similar to that found 
by Nishimum et al. (7) in relatively asymptomatic patients 
with mitral valve prolapse as well as concurrent control 
patients, that is, an 8 year actuarial survival of 58% in 237 
patients with a mean age of 44 years and a mean follow-up 
interval of 6.2 yews. Thus, age, risk factor and disease 
adjustments in addition to concurrent contmls are all neces- 
sary to detect the presence or absence of m, exess sudden 
death or mortality rate. 
Similarly, the absence of case-matched controls con- 
founds the interpretation of the rate of occurrence of endo- 
carditis and stroke. The stablization of the activitv of the 
cerebral isehemic events atIer I year of therapy is c&sistent 
with the suggestions of others (8) and, although preliminary, 
is an interesting point of focus for future studies. 
HlslOrlcat prspwtive mid E”rr& WILvideraticas. After 
Reid (9) and Barlow and Pocwk (IO! fwused our attention 
on mitral valve prolapse, complications (1 I) including chest 
pain, arrhythmia, infective endocatditis, progressive mitral 
regurgitation, stroke and sudden death were described. This 
information, especially when ccmbined with echocardio- 
graphic repons of high disease prevalence (12). produced a 
period of “pmlapse paranoia.” However, it is now sug- 
gested (6.13) that symptoms of chest pain, fatigue, dyspnea, 
dizziness and anxiety attacks; inferolateml T wave abnormal- 
ities: atrial premature beats, simple and complex ventricular 
arrhythmias; and mild mitral valve displacement, especially 
on the four-chamber two-dimensional echocardiogmphic 
view (14) are nonspecific findings. Focal neumlogie attacks 
oramaurosis fugax in the young patient, first degree relatives 
with prolapse, documented recurrent supraventricular 
tachycardia, asthenic body habitus and thoracic bony abnor- 
malities may now be viewed as minor criteria (6). Specific 
physical and diagnostic findings are more conservatively 
defined (61, for example, 3 mm of valve displacement are 
suggested when using echocardiography. 
Pocock (IS) discourages mformtng the asymptomat~ 
patient with an isolated click or prolapse detected only by 
echocardiography of their Endings. Stress ~ectmg IS usually 
avoided unless needed for insurance, qport~ act~vmcs or 
employment purposes, and endocarditis prophylaxn is pre- 
scribed only whenatnumurts present. DespiteaS- to IO-fold 
increase in the risk of endocarditts in the presence of mttral 
valve prolapse and murmur (lb). the overilll incidcncc of 
eodocarditis remains low. about I I” Z.wO persons per year 
compared with L in 2WOtJ persons per year in the genera! 
U.S. adult population (6.17). Definitive resommendationc 
for endocarditir prophylaxis will require tdentification of 
risk-specific markers (18). The need to tdentlfy vtch a high 
risk population is emphasized by the pattents of Duren et al. 
(I) with endocarditis, many of whom had a poor clinical 
o”t0Mlte. 
Ma!tagemenf of symproma~ic ~~rienrs is more difficult 
because many of their symptoms may not be disease spafic 
(6.13). Svmotomatic theraDv for chest oain or oalaitatton. 
;hort-te& iherapy to p&&t stroke ;ecurre&e ‘and the 
identification and treatment of symptomatic bmdyarrhyth- 
mia and tacbyarrhythmia is advised; treatment should al- 
ways utilize the most benign intervention (15). Follow-up is 
targeted to the evaluation for progressive mitral regurgtta- 
tion which, as in the patients tudied by Duren et al. (I). may 
occur in IO to 15% of patients with mitral valve prolapse 
(6,19,20). Chordal t’“Qt”E spontaaneour or related to endo- 
carditis, may hasten the process (20. Prolapse is now a 
leading cause of mitral valve replacement for isolated mitral 
regurgitation (22). Although occ~stonal patients with pm- 
lapse will need aggressive attention to arrhythmia (23.24). 
many of the risks that have been associated with mitral valve 
prola~re, includingeodocarditis, hera failure and arrhythmia. 
seem to be coincident with vatvutor egurgitation. indeed. 
mitral valve prolapse is evolving into an interesting cause of 
mitral regutgitation ratbet than inio a unique syndrome. 
Cancludi~remnrb. Future studies will require a consea- 
stts as to what constitutes “pathologic” prulapse and they 
must adhere to the strict srincitdes of epidemiolotic study. 
Abnormal diastolic coaptaiion of the m&l lcaflets~elated io 
relative hypovolemia or a thin body habitus is probably not 
patbologic. However, mitral valve redundancy (7) and the 
presence of regurgitation (4,7,19.20) are associated witb 
higher complication rates. Duren et al. (I) obviously did not 
have the benefit of these observations when they began their 
study. ‘Tbev did movide us with a report that has the strencth 
of l&-t& observations and that reinforces the oeedto 
carefully follow up selected patients with mitral valve pro- 
lapse, particularly those with mitral regurgitation. However, 
it is probably wise to continue to stress the benign aspects of 
mitral valve prolapse even in the “symptomatic” patient. 
